Charlotte Teunissen aims to improve patient for neurological diseases by body fluid biomarkers for diagnosis, stratification, prognosis and monitoring of treatment responses. Studies of her research group span the entire spectrum of biomarker development, from biomarker identification, using –omics methods, followed by assay development, analytical and clinical validation, and lastly implementation in clinical practice and trials.
Her young and dynamic lab has extensive expertise with state of the art technologies, such as various ultrasensitive and antibody-based assays, and vitro diagnostics for clinical routine lab analysis. She is responsible for the large biobank of the Amsterdam Dementia cohort, containing >10000 paired CSF and plasma/serum samples of individuals visiting the memory clinic of the Alzheimer Center Amsterdam. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers and the Body fluid Biomarkers PIA, and the recently founded Coral proteomics consortium. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers, and the JPND bPRIDE project, that aims to develop blood based biomarkers for early differential diagnoses of specific dementias.